Citadel Advisors’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Citadel Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-16,056	Closed	-$147K	–	10532
2019 Q4	$147K	Sell	16,056 -1,390	-8%	-$16.9K	﹤0.01%	8377
2019 Q3	$294K	Sell	17,446 -3,834	-18%	-$57.1K	﹤0.01%	7586
2019 Q2	$286K	Sell	21,280 -1,094	-5%	-$16.4K	﹤0.01%	7658
2019 Q1	$297K	Sell	22,374 -1,357	-6%	-$19.7K	﹤0.01%	7628
2018 Q4	$519K	Buy	+23,731	New	+$436K	﹤0.01%	6338

Other funds holding ZBIO

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's ZBIO Position: Q1 2020 in Review

Citadel Advisors sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q1 2020, closing a stake of 16,056 shares — an estimated $147K sold.

Citadel Advisors first reported a position in ZBIO in Q4 2018 and held it in 5 quarters. The position peaked at $519K in Q4 2018. 1 fund tracked by Wall St. Rank holds ZBIO as of Q1 2020.

Citadel Advisors reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
Citadel Advisors sold 16,056 ProShares UltraPro Short NASDAQ Biotechnology shares in Q1 2020, an estimated $147K.
Citadel Advisors first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q4 2018 and held it in 5 quarters.
Citadel Advisors's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $519K in Q4 2018.
1 fund tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q1 2020.

Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.